{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:26Z","timestamp":1781650706816,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with von Hippel-Lindau-associated central nervous system hemangioblastoma (VHL-CNS-Hb) have a large economic burden, but there is limited real-world evidence describing their clinical burden in the United States (US). This study compared treatment patterns and monitoring procedures between patients with VHL-CNS-Hb and matched controls in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with VHL-CNS-Hb and matched controls were identified from Optum\u2019s de-identified Clinformatics\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Data Mart Database. The index date was the date of first CNS-Hb diagnosis (VHL-CNS-Hb cohort) or the date of a random medical claim within the patient\u2019s claims (control cohort). Treatment patterns were assessed in the VHL-CNS-Hb cohort using unadjusted incidence rates. Pain management drug use, disease monitoring procedures, and visits to medical specialists were compared between cohorts using unadjusted and adjusted generalized linear models. Clinical trial number: not applicable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most common treatment observed in the VHL-CNS-Hb cohort (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009220) was targeted therapy for renal cell carcinoma (2.34 treatment events per 10 person-years). Pain management drug use, monitoring, and specialist visits peaked during the first\/second year post-index. Compared to controls (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091100), VHL-CNS-Hb patients had higher rates of pain management drug use (adjusted incidence rate ratio [IRR]: 1.96), monitoring procedures (adjusted IRR: 3.93), and specialist visits (adjusted IRRs: 2.49\u201325.44; all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009\u2264\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with VHL-CNS-Hb had a substantial, long-term clinical burden that included treatment for multiple VHL manifestations\u2014reflecting the multi-organ nature of the disease\u2014frequent pain management drug use, and high levels of healthcare use for disease monitoring and specialist visits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00337-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:12:35Z","timestamp":1776697955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monitoring and treatment patterns of von Hippel-Lindau disease-associated central nervous system hemangioblastomas"],"prefix":"10.1186","volume":"24","author":[{"given":"Eric","family":"Jonasch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Freimark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"337_CR1","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.2147\/OTT.S190753","volume":"13","author":"S Glasker","year":"2020","unstructured":"Glasker S, Vergauwen E, Koch CA, et al. Von Hippel-Lindau Disease: Current Challenges and Future Prospects. Onco Targets Ther. 2020;13:5669\u201390.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"337_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.clgc.2022.12.008","volume":"21","author":"E Jonasch","year":"2023","unstructured":"Jonasch E, Song Y, Freimark J, et al. Epidemiology and economic burden of Von hippel-lindau disease-associated renal cell carcinoma in the United States. Clin Genitourin Cancer. 2023;21(2):238\u201347.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"337_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4132\/jptm.2022.04.13","volume":"56","author":"RA Yoda","year":"2022","unstructured":"Yoda RA, Cimino PJ. Neuropathologic features of central nervous system hemangioblastoma. J Pathol Transl Med. 2022;56(3):115\u201325.","journal-title":"J Pathol Transl Med"},{"issue":"6","key":"337_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3171\/2021.3.JNS204203","volume":"136","author":"K Huntoon","year":"2022","unstructured":"Huntoon K, Shepard MJ, Lukas RV, et al. Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease: a consensus statement. J Neurosurg. 2022;136(6):1511\u20136.","journal-title":"J Neurosurg"},{"issue":"10","key":"337_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00381-020-04712-5","volume":"36","author":"JH Klingler","year":"2020","unstructured":"Klingler JH, Glasker S, Bausch B, et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020;36(10):2537\u201352.","journal-title":"Childs Nerv Syst"},{"key":"337_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.37349\/en.2023.00031","volume":"2","author":"C Sanghadia","year":"2023","unstructured":"Sanghadia C, Martinez M, McNulty M, et al. Emerging therapies of hemangioblastomas. Explor Neurosci. 2023;2:318\u201330.","journal-title":"Explor Neurosci"},{"key":"337_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers14215313","volume":"14","author":"V Narayan","year":"2022","unstructured":"Narayan V, Jonasch E. Systemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease. Cancers (Basel). 2022;14:21.","journal-title":"Cancers (Basel)"},{"key":"337_CR8","unstructured":"National Cancer Institute. Von Hippel-Lindau Disease (PDQ\u00ae)\u2013Health Professional Version 2024 [cited 2024 April 4]. Available from: https:\/\/www.cancer.gov\/types\/kidney\/hp\/renal-cell-carcinoma-genetics\/vhl-syndrome"},{"issue":"1","key":"337_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-024-03060-w","volume":"19","author":"E Jonasch","year":"2024","unstructured":"Jonasch E, Song Y, Freimark J, et al. Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States. Orphanet J Rare Dis. 2024;19(1):73.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"337_CR10","doi-asserted-by":"publisher","first-page":"11144","DOI":"10.1038\/s41598-018-29047-9","volume":"8","author":"Y Huang","year":"2018","unstructured":"Huang Y, Chan L, Bai HX, et al. Assessment of care pattern and outcome in hemangioblastoma. Sci Rep. 2018;8(1):11144.","journal-title":"Sci Rep"},{"key":"337_CR11","doi-asserted-by":"crossref","unstructured":"Cavalli E, Mammana S, Nicoletti F, et al. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419838383.","DOI":"10.1177\/2058738419838383"},{"key":"337_CR12","doi-asserted-by":"crossref","unstructured":"Jonasch E, Song Y, Freimark J, et al. Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States. Clin Genitourin Cancer. 2025 Apr;4:102349.","DOI":"10.1016\/j.clgc.2025.102349"},{"issue":"22","key":"337_CR13","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021;385(22):2036\u201346.","journal-title":"N Engl J Med"},{"key":"337_CR14","unstructured":"US Food and Drug Administration. FDA approves belzutifan for cancers associated with von Hippel-Lindau disease 2021 [cited 2024 April 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belzutifan-cancers-associated-von-hippel-lindau-disease"},{"issue":"16suppl","key":"337_CR15","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2023.41.16_suppl.2008","volume":"41","author":"O Iliopoulos","year":"2023","unstructured":"Iliopoulos O, Bundsbaek A, Iversen B, et al. Belzutifan treatment for von Hippel-Lindau (VHL) disease\u2013associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study. J Clin Oncol. 2023;41(16suppl):2008.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"337_CR16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/JCO.2023.41.16_suppl.2078","volume":"41","author":"O Iliopoulos","year":"2023","unstructured":"Iliopoulos O, Rapalino O, Barker F, et al. Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience. J Clin Oncol. 2023;41(16suppl):2078.","journal-title":"J Clin Oncol"},{"issue":"1","key":"337_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11060-023-04395-3","volume":"164","author":"BJ Neth","year":"2023","unstructured":"Neth BJ, Webb MJ, White J, et al. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience. J Neurooncol. 2023;164(1):239\u201347.","journal-title":"J Neurooncol"},{"issue":"3","key":"337_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2337\/dc13-2176","volume":"37","author":"JB Rice","year":"2014","unstructured":"Rice JB, Desai U, Cummings AK, et al. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37(3):651\u20138.","journal-title":"Diabetes Care"},{"issue":"4","key":"337_CR19","first-page":"426","volume":"28","author":"A Mostaghimi","year":"2022","unstructured":"Mostaghimi A, Gandhi K, Done N, et al. All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. J Manag Care Spec Pharm. 2022;28(4):426\u201334.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00337-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00337-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:25:35Z","timestamp":1781648735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13053-026-00337-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00337-y","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with applicable ethical principles, including those outlined in the Declaration of Helsinki. The data used in this study were de-identified and comply with the patient privacy requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). As the study used de-identified secondary data and did not involve direct interaction with human subjects, Institutional Review Board (IRB) review was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Part of the material in this manuscript was presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting held May 31 \u2013 June 4, 2024, in Chicago, Illinois, United States, and online as a poster presentation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentations"}},{"value":"EJ has received research funding from Arrowhead, Merck, and NiKang, as well as honoraria from Aveo, Aravive, Calithera, Eisai, Exelixis, Ipsen, Merck, NiKang, Novartis, Pfizer, and Takeda. YS, JF, MM, and JS are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to MSD, which funded the development and conduct of this study and manuscript. MS is an employee of MSD.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}